RET Inhibitors in Advanced NSCLC, Tanya Guel-Pérez, MD

RET Inhibitors in Advanced NSCLC, Tanya Guel-Pérez, MD

Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung CancersПодробнее

Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung Cancers

Emerging Agents and Combinations to Treat RET Fusion-Positive Lung CancersПодробнее

Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLCПодробнее

Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLC

RET Inhibition Research: Next StepsПодробнее

RET Inhibition Research: Next Steps

From Variant Functionality to Resistance in CancerПодробнее

From Variant Functionality to Resistance in Cancer

Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLCПодробнее

Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLC

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET f...Подробнее

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET f...

Targeted therapies (i.e.: multi-kinase inhibitors, RET, NTRK inhibitors) in advanced disease. 251Подробнее

Targeted therapies (i.e.: multi-kinase inhibitors, RET, NTRK inhibitors) in advanced disease. 251

Treatment of NSCLC With RET FusionsПодробнее

Treatment of NSCLC With RET Fusions

Targeting RET Alterations With Selective Inhibitor BLU-667Подробнее

Targeting RET Alterations With Selective Inhibitor BLU-667

RET inhibition in RET aberrant cancersПодробнее

RET inhibition in RET aberrant cancers

Part 1 Investigator Insights: Emerging Multikinase Inhibitors in the Treatment of Thyroid CancersПодробнее

Part 1 Investigator Insights: Emerging Multikinase Inhibitors in the Treatment of Thyroid Cancers

Next steps in NSCLC: checkpoint inhibitors plus cellular therapyПодробнее

Next steps in NSCLC: checkpoint inhibitors plus cellular therapy

Part 2 Investigator Insights: Emerging Multikinase Inhibitors in the Treatment of Thyroid CancersПодробнее

Part 2 Investigator Insights: Emerging Multikinase Inhibitors in the Treatment of Thyroid Cancers

Targeted therapy for NTRK fusion-positive cancersПодробнее

Targeted therapy for NTRK fusion-positive cancers

When Should I Combine Checkpoint Inhibitors & Chemotherapy in Frontline Treatment of Advanced NSCLC?Подробнее

When Should I Combine Checkpoint Inhibitors & Chemotherapy in Frontline Treatment of Advanced NSCLC?

LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLCПодробнее

LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLC

Selecting and Managing RET-Targeted Therapy in mNSCLCПодробнее

Selecting and Managing RET-Targeted Therapy in mNSCLC